about
Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndromeOutcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study.Polycythemia Vera Management and Challenges in the Community Health Setting.Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Darbepoetin alfa for anemia with myelodysplastic syndrome.Established and novel agents for myelodysplastic syndromes.Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia.Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?The association of histologic grade with acute graft-versus-host disease response and outcomes.Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection.Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decisionSocial Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.Time, timing, and the treatment of diffuse large B-cell lymphoma.
P50
Q28831412-7D8A1A25-4E34-40C1-9CB4-2187764B71F0Q30252975-EDC7FD46-0CD7-4AF6-A964-E794078C0006Q30274942-184B20DF-5855-4ACF-A298-074C4AE205B3Q30353404-ABDBB80F-C901-4986-A43F-F075535F468FQ30402304-9A0325D2-E2BE-4747-AD6B-48094566D5CDQ33803036-0647897A-838C-4677-BA34-B4D5D280554BQ36806501-DDD66090-D8AD-40B7-99A9-103F30A884F1Q37457111-9ED0E6B7-8585-4292-97FF-FBCDD2633EB0Q38246598-C33ADB5E-8D57-4466-B0A1-811B1332EDC6Q38314705-3B8489DA-94EC-42D6-8DA6-F77F272B628BQ38361585-34BCE77D-EA68-4731-8098-52ED87193962Q38537896-746EDB50-DC20-4BEA-911D-7B1390C995B8Q38619079-1BF048C5-6C8C-4ECA-B75A-B6D516AA7568Q38644826-D0C5D9A1-2F1F-4C29-AF9B-69F2AD7A800BQ38767865-5F6C58E9-E8B0-4835-824D-88C37958FCA0Q38774457-A774EFFF-C9B0-4EA8-A6DD-AB7270BA7A3EQ38855365-AFF1681B-D290-4E47-8C4F-C6570AEB1012Q38876814-770B67A8-4A81-4EE6-99E7-121F39BDD1B2Q39048645-23DB278A-CE6B-4BF8-9991-5E49CE63B973Q39904388-5CA5FCE5-1B9F-465F-B5E6-E81264F2F905Q40067975-4455A1E4-1A9E-4AA0-94F1-5852FEA9CC84Q40369741-3C1C572B-8647-4181-9FB6-A7E888FA149BQ40718203-9C2851FE-2C38-4B1E-A0B5-3CD46BB95A9EQ41704218-225E3244-396A-4EDE-AB70-8E4489763889Q41879404-FD7AA74C-25E0-4563-BA19-1A14D823DEE2Q43255525-6D352C3C-1898-4F3B-B45B-9EF919279B9CQ47363575-659107AB-6434-47EE-9B04-B1E2E721E118Q47567746-C00FFA01-9C2A-4AAF-B904-E48A6A07E294Q47567814-B39B91C8-6BC5-488E-A827-7FFADFD53B78Q47606460-9150EC95-4A23-4D10-A91A-EB99ACC11D13Q47609603-F8FC3666-A566-42EC-B98F-D67E93ABD114Q47655977-1E0B89E1-DB22-47C7-A499-411E0CBAEA37Q48155873-965E02E3-C47C-4648-A14E-D16BA0D9CA6DQ48256771-5D5F6189-7D30-4304-9D42-DA07B9BB2517Q48267407-527FD3EC-213C-41CE-8D2A-2AD329A50C91Q49679915-608BF70A-3D76-4E4F-8624-BCB53797268AQ50216037-1682087E-27D1-4428-BB34-3FA780304927Q50537925-3598B9CB-30A5-4F0C-9ABD-F2943434C6D1Q51776458-80106795-C2F7-4F43-AB24-4A2E518305D8Q53435280-44641743-26A1-4E63-96B9-414D3314DAD6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aaron T Gerds
@ast
Aaron T Gerds
@en
Aaron T Gerds
@es
Aaron T Gerds
@nl
Aaron T Gerds
@sl
type
label
Aaron T Gerds
@ast
Aaron T Gerds
@en
Aaron T Gerds
@es
Aaron T Gerds
@nl
Aaron T Gerds
@sl
prefLabel
Aaron T Gerds
@ast
Aaron T Gerds
@en
Aaron T Gerds
@es
Aaron T Gerds
@nl
Aaron T Gerds
@sl
P106
P2038
Aaron_Gerds
P21
P31
P496
0000-0002-3422-1309